VYCOR MEDICAL, INC.

BOCA RATON, FL – April 15, 2025 (NEWMEDIAWIRE) – Vycor Medical, Inc. (“Vycor”) (OTCQB-VYCO), today announced financial results for the year ended December 31, 2024. The company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision®, which offers therapy programs to help patients recover visual disorders after stroke or brain injury and remains a business in development. Company Highlights The Vycor Medical division revenues increased by 10% over 2023 with most of the growth coming from increased US penetration; sales to US hospitals were up 17% during the period with 11 new US hospitals added. Gross margins remain strong at around 90%. The Company continues to invest in new product development in the Vycor Medical division. During 2024, eight new peer-reviewed studies were published on the ViewSite Brain Access System (VBAS), including a significant 106-patient study evaluating its effectiveness in glioma removal. Gliomas are a type of brain tumor that arises from glial cells, which support nerve cells in the brain. Another study involving 22 patients concluded: “VBAS allows for complete cyst removal with minimal complications, offering the benefits of less invasiveness, improved visualization, and reduced tissue disruption, strengthening its […] The post Vycor Medical Releases Financial Results for the Year Ended December 31, 2024 appeared first on Vycor VBAS.

BOCA RATON, FL, June 30, 2020 — Vycor Medical, Inc. (“Vycor”) (OTCBB-VYCO) today announced that its wholly owned subsidiary, NovaVision, Inc. (“NovaVision”), has signed an agreement in principle to enter into an exclusive licensing agreement with HelferApp GmbH (“HelferApp”). Under the terms of the agreement HelferApp will have the exclusive rights for NovaVision’s diagnostic products and therapies provided direct to the patient and to medical professionals in Germany, Austria and Switzerland. The combination of the NovaVision therapies will allow HelferApp to create an unrivalled portfolio of scientifically supported therapies addressing the visual rehabilitation market in the territories. This transaction follows Vycor’s statement in May that it intended to close NovaVision’s German office and evaluate a transition to a license model for NovaVision in Europe. This complementary transaction with HelferApp provides a validation for a license-based model. NovaVision will seek internationally to partner with strong regional companies who will be better able to leverage NovaVision’s clinically supported vision therapies. The cooperation of NovaVision and HelferApp opens new paths in digital care, with potentially significant benefits in digital teletherapeutic rehabilitation and better patient outcomes. HelferApp will also drive the adoption of NovaVision’s NeuroEyeCoach saccadic training program, which was the subject of a […] The post Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement appeared first on Vycor VBAS.

BOCA RATON, FL, March 27, 2020 — Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2019. Highlights The Vycor Medical division recorded revenue of $1,300,000 from the sale of its products for the year ended December 31, 2019, a decrease of $11,000 (or 1%) over 2018. The US continued to experience growth (increase of 28%), primarily as a result of greater adoption and usage following the introduction of the enhanced VBAS model in September 2017, however this was offset by two large international orders in the 2018 period which were not repeated during 2019. Gross margin was 90% compared with 88% in 2018. Operating expenses for the year were $2,060,000, a reduction of $597,000 or 22% compared to 2018, despite a significant increase in regulatory fees due to the migration to a new EU Notified Body for VBAS and despite increased patent fees due to the filing of 8 new patents for VBAS during the year. Operating loss was $725,000 compared to $1,318,000, a reduction of 45%, and Cash Operating Loss1 was $121,000 compared to $207,000, a reduction of 42%. Net Loss for […] The post Vycor Medical Reports Financial Results for the year ended December 31st, 2019 appeared first on Vycor VBAS.

BOCA RATON, FL, Feb. 27, 2020 — Vycor Medical, Inc. (OTCQB: VYCO) Jose Romano, Chief of the Stroke Division at the University of Miami Miller School of Medicine, co-authored a recently published international study that shows that visual rehabilitation is effective for patients who have suffered vision loss related to stroke or traumatic brain injury. The study titled “Efficacy and predictors of Recovery of Function After Eye Movement Training in 296 Hemianopic Patients,” was recently published in the journal Cortex. Led by the University of Aberdeen, it is the largest neuro-visual study of its kind. The research team found that the NeuroEyeCoach visual rehabilitation therapy applied after stroke or other traumatic brain injury (TBI) improved vision in over 80 percent of patients, helping them with everyday tasks and improving their quality of life. The results showed that the treatment improved vision even in an 90-year-old patients. “Up to recently, there was very little treatment available to restore vision loss in this population,” said Romano, noting that while stroke and TBI patients regain some vision on their own, “very few regain it completely.” Blindness among these patients usually stems from injury to the back of the brain where images are interpreted. […] The post New Study Shows Vision Rehab Treatment Effective for Stroke and Injury Related Blindness appeared first on Vycor VBAS.

A new treatment has been found to be successful in improving the vision of partially blind patients. Boca Raton, FL, Feb. 26, 2020 — Funded by Vycor Medical, Inc. (OTCQB: VYCO) subsidiary NovaVision, Inc., and led by Professor Arash Sahraie from the School of Psychology, the study is the largest study of its kind to evaluate this new programme of treatment which is aimed at those with sight loss following brain injury. In collaboration with University of Miami Miller School of Medicine and NovaVision, Inc., researchers found that the NeuroEyeCoach programme for rehabilitation of blindness after stroke, or other brain injury improved vision in over 80% of patients. Published in the scientific journal Cortex, the study involved almost 300 patients, the largest number of patients to participate in a study like this. Professor Sahraie explains: “Blindness after brain injury is common and its effect on patient’s daily life is sudden. Those affected have great difficulty finding their way around and avoiding obstacles. This therapy is designed to help this group of patients. “We found that following treatment, patients’ ability to detect and avoid obstacles improved, they are also seeing things much faster and also state that the therapy improved their […] The post Treatment for blindness successful in largest ever study appeared first on Vycor VBAS.

Enhanced VBAS Facilitates its Integration with Image Guidance Pointers BOCA RATON, Florida, March 6, 2018 — Vycor Medical, Inc. (OTCQB: VYCO) had previously announced in October 2017 to its customer base the release of its enhanced VBAS, which it would be slowly rolling out over the course of this year as it ran down its inventory of the current VBAS. Following surgeon feedback Vycor has decided that it will from now be shipping only the enhanced model VBAS across the complete main range of 12 VBAS sizes. As previously announced the Company has been working on improving how its VBAS integrates with the most common Image Guidance System (“IGS”) pointers on the market. The Company believes that the enhanced VBAS model that is now being shipped across the main range should make the use of a pointer more intuitive and easy. This has involved molding a cup inside the bottom end of the introducer part of the VBAS. The purpose of the cup is to enable the pointer to be rested at the bottom of the introducer without protruding through the hole at the tip, and also help center the pointer in the device. The cup has been designed in […] The post Vycor Announces That it is Accelerating the Roll-out of its Enhanced VBAS due to Surgeon Feedback appeared first on Vycor VBAS.

BOCA RATON, Florida, September 28, 2016 — Vycor Medical, Inc. (“Vycor”) (OTCQB-VYCO) reports that a new peer-reviewed study published in “BioMed Research International” shows improvements in visual search following the use of NovaVision’s NeuroEyeCoach. The three-centre study was conducted by the School of Psychology of University of Aberdeen, the Neuromotor and Cognitive Rehabilitation Research Centre of University of Verona, and the Department of Psychology of University of Munich. The Paper concludes that NeuroEyeCoach is an effective compensatory approach for those with homonymous visual field loss. The training led to faster visual search times, reduction in the number of errors made, and improvements in reported activities of daily living. Professor Arash Sahraie, Head of the School of Psychology at the University of Aberdeen commenting on the findings stated “It’s important to develop techniques to help patients to compensate for their sight deficits and NeuroEyeCoach is providing a much needed step forward in providing therapy for these patients. We have used this type of compensatory technique in vision research for some time now and we value the importance of developing the existing vision in order to improve the quality of life for the individual. In NeuroEyeCoach, we have developed the research into […] The post New Clinical Study on NeuroEyeCoach Conclusively Supports Meaningful Improvement in Eye Movement Efficiency appeared first on Vycor VBAS.

BOCA RATON, Florida, March 16, 2016 — Vycor Medical, Inc. (“Vycor”) (OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it has launched the VBASMini, the smallest and most minimally invasive model in its range of ViewSite Brain Access System devices. The VBASMini was developed in close collaboration with a leading neurosurgeon who had identified a need to develop a much smaller VBAS than those currently available to allow for less invasive surgery yet still enable the use of instruments. The VBASMini is the largest clear device available that can fit through a burr hole yet still provides a large enough working channel to be useful in neurosurgery, and was designed to overcome the limitations of carrying out work through the likes of an endoscopic sheath. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles. The VBASMini comes in two lengths and is half the diameter of Vycor’s current smallest VBAS device and is now available for purchase. The VBASMini can retrieve a larger specimen than through a conventional neuro-endoscope and can be used to remove intracerebral hematomas, drain abscess, remove an intra-ventricular tumor […] The post Vycor Medical Launches VBASMini appeared first on Vycor VBAS.